Enhancing neuronal resistance to neurodegeneration by targeting RNA-binding proteins

Technology
Conceptual
University
Scouted & summarized by Halo AI

A platform for identifying and modulating intrinsic neuronal resistance mechanisms to combat neurodegenerative diseases like ALS and FTD. By leveraging stem cell-derived neuron models, the technology targets RNA-binding protein pathways and proteostasis to enhance neuronal survival and prevent disease-driven degeneration. Available for licensing.

Overview

This technology provides a novel platform for developing neuroprotective therapies by targeting the intrinsic cellular mechanisms that grant specific neurons resistance to neurodegeneration. By studying cranial motor neurons, which naturally resist Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) stress, researchers have identified key regulatory pathways—specifically involving RNA-binding proteins and proteostasis—that can be manipulated to protect vulnerable spinal motor neurons. This approach offers a potential paradigm shift, moving from symptomatic treatment to altering the intrinsic vulnerability of neurons to prevent or reverse disease progression.

Technical specifications

The technology centers on a scalable human induced pluripotent stem cell (iPSC) differentiation platform that generates highly pure populations of both ALS-resistant cranial motor neurons and ALS-sensitive spinal motor neurons. Key capabilities include:

  • Regulation of RNA-binding proteins to prevent pathological splicing defects and protein mislocalization.
  • Enhancement of proteasome-mediated protein degradation to maintain proteostasis and prevent toxic protein aggregation.
  • Identification of molecular signatures and transcriptional profiles that distinguish resilient neurons from susceptible ones.
  • A high-throughput screening platform suitable for testing therapeutic candidates against ALS-related proteotoxic stress.
Technology readiness level

The technology is at a stage of preclinical validation. It has successfully moved from basic research to the development of robust iPSC modeling systems that demonstrate differential sensitivity in vitro. The methodology is currently supported by pending provisional patent applications, and researchers are actively validating protective mechanisms in relevant models to support future therapeutic translation. Estimated TRL: 3.

Generated Jul 8, 2026. Please verify key information.

About New York University

New York University is a comprehensive private research university anchored in New York City, enrolling a large, diverse student body and operating a global network of campuses. Corporate engagement is enabled by co‑located engineering and computing hubs in Brooklyn and Manhattan with shared labs and facilities for prototyping and field pilots. Integration with a major hospital system supports clinical translation, IRB processes, and access to real‑world data under stringent governance. Proximity to leading industries and a mature sponsored‑research function streamline scoping, NDAs, MSAs, and talent pipelines. Research is supported by competitive federal funding from agencies such as NIH, NSF, DOE, and DOD, and a dedicated technology transfer office manages IP, licensing, and startup creation.

Halo home
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.